Cytotoxic and Antitumoral Effects of Bikaverin Isolated from *Gibberella fujikuroi* on L5178Y Lymphoma Murine Model

Gabriela Hinojosa-Ventura[1,*], Ana María Puebla-Pérez[1], Martha Patricia Gallegos-Arreola[2], Ma. del Carmen Chávez-Parga[3], Antonio Romero-Estrada[4], Jorge Iván Delgado-Saucedo[1].

[1]Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Jalisco, México.
[2]Centro de Investigación Biomédica de Occidente, I.M.S.S., Guadalajara 44340, Jalisco, México.
[3]Departamento de Ingeniería Química, Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58030, Michoacán, México.
[4]Centro de Investigaciones Químicas, Universidad Autónoma del Estado de Morelos, Cuernavaca 62209, Morelos, México.

*Corresponding author: Gabriela Hinojosa-Ventura, e-mail: ybag402_7@hotmail.com Tel.: +52-331-3785900

Abstract. In this work, bikaverin was isolated from the mycelium of *Gibberella fujikuroi* and characterized using 1D (^1H and ^{13}C) and 2D (HSQC and HMBC) NMR spectroscopy. Its cytotoxic effect on L5178Y lymphoma cells and antitumor effect on BALB/c mice inoculated with L5178Y cells were evaluated. According to the results, bikaverin showed cytotoxic effect against L5178Y lymphoma cells with an IC_{50} value of 0.23 μg/mL.The tumor evolution, with and without treatment, was observed in the *in vivo* study; the group without treatment showed $1,280\pm128$ x 10^5 cells/mL in ascites volume, and the groups treated with bikaverin at the dose of 1.73 mg/kg/day by intraperitoneal (i.p.) and oral administration, decreased significantly the cell density, and showed 391.5 ± 237 x 10^5 cells/mL and 580 ± 208 x 10^5 cells/mL, respectively. The results confirm the cytotoxic effect of bikaverin on cancer cell lines and contribute to show the potential of bikaverin as antitumoral compound in BALB/c mice inoculated with L5178Y lymphoma cells.
Keywords: *Gibberella fujikuroi*; bikaverin; polyketide; cytotoxic and antitumoral effects.

Resumen. En este trabajo, se reporta el aislamiento de bikaverina a partir del micelio de *Gibberella fujikuroi*, cuya estructura fue elucidada mediante el uso de la espectroscopia de RMN en 1D (^1H y ^{13}C) y 2D (HSQC y HMBC). Se evaluó su efecto citotóxico en células de linfoma L5178Y y su efecto antitumoral en ratones BALB/c inoculados con células L5178Y. De acuerdo con los resultados, la bikaverina mostró efecto citotóxico contra las células de linfoma L5178Y con un valor de CI_{50} de 0.23 μg/mL. En el estudio *in vivo* se observó la evolución del tumor, con y sin tratamiento, donde el grupo sin tratamiento mostró $1,280\pm128$ x 10^5 células/mL en el volumen de ascitis, y los grupos tratados con bikaverina a la dosis de 1.73 mg/kg/día, administrada de forma intraperitoneal (i.p.) y oral disminuyeron significativamente la densidad celular, mostrando 391.5 ± 237 x 10^5 células/mL y 580 ± 208 x 10^5 células/mL, respectivamente. Los resultados obtenidos confirman el efecto citotóxico de bikaverina sobre líneas celulares de cáncer y contribuyen a mostrar su potencial como compuesto antitumoral en ratones BALB/c inoculados con células de linfoma L5178Y.
Palabras clave: *Gibberella fujikuroi*; bikaverina; policétido; efecto citotóxico y antitumoral.

Introduction

Cancer is one of the most important causes of death worldwide and is expected to rank as the leading in the 21st century. It is estimated that this disease caused 9.5 million deaths worldwide in 2018 [1]. Currently, there are many types of cancer treatment, but chemotherapy is one of the most widely used. However, because of the severe side effects exhibited by drugs used in the treatment of cancer and the drug resistance in tumor cells, novel agents and treatment strategies are necessary [2,3]. According to the Food and Drug Administration (FDA), 246 anticancer drugs were approved during the 1940-2014 period, around 38% of which were natural products or derived from them [4]. In this context, one important source of bioactive secondary metabolites is fungi. This is supported by the various reports about secondary metabolites isolated from fungi. An example is the bioactive polyketide named bikaverin ($C_{20}H_{14}O_8$) [5-7]. This compound is produced by several fungal species, mainly from the genus *Fusarium*. Specially, it has been isolated from the *G. fujikuroi* (*Fusarium fujikuroi*) fungus [8,9]. Bikaverin has shown biological effects such as antiprotozoal, antifungal, nematicidal, and neuroprotective effect [10-13]. In addition, this compound has shown cytotoxic effect against different cancer cell lines at different concentrations [14-17]. For the current research, bikaverin was produced by *G. fujikuroi* fungus in a bioreactor under controlled conditions [18] and later isolated and characterized with the purpose of evaluating the cytotoxic effect against L5178Y lymphoma cells and the antitumoral effect on L5178Y lymphoma murine model.

Experimental

Material and Methods
Chemicals

Penicillin-streptomycin, RPMI 1640 medium and fetal bovine serum were obtained from Gibco (Carlsbad, CA, USA). Cyclophosphamide, bikaverin standard, dimethyl sulfoxide (DMSO), silica gel 60, oxalic acid, chloroform, methanol, acetic acid, chloroform-d ($CDCl_3$) and trifluoroacetic acid-d (CF_3COOD) were obtained from Sigma-Aldrich. The quick cell proliferation assay kit WST-1 was purchased from Biovision Inc., (Milpitas, CA, USA).

Bikaverin Production, Extraction and Isolation

Bikaverin was produced by *G. fujikuroi* fungus in a bioreactor under controlled conditions and extracted as previously described [18]. A sample (210 mg) of ethyl acetate extract was subjected to normal-phase column chromatography using a mixture (13 g) of silica gel 60:oxalic acid (95:05, w/w) and eluted with a mixture of chloroform:methanol:acetic acid (94:1:5, v/v/v). As a result, 40 fractions of 5 mL were collected. The fractions were monitored and compared with bikaverin standard by normal-phase thin layer chromatography. After this, the fractions with bikaverin were precipitated with methanol at -70 °C during 24 h, and 63 mg of pure bikaverin was obtained.

Spectroscopic Data

Bikaverin was characterized by NMR in a Varian VNMRS (700 MHz) spectrometer at 700 MHz for ^{1}H-NMR and 175 MHz for ^{13}C-NMR. The 1D (^{1}H and ^{13}C) and 2D-NMR (HSQC and HMBC) experiments were recorded in a mixture of chloroform-d ($CDCl_3$) and trifluoroacetic acid-d (CF_3COOD) (1:1, v/v). Chemical shifts (δ) are expressed in parts per million (ppm) relative to TMS as an internal standard.

Cytotoxic Assay

The L5178Y lymphoma cells (5 x 10^4 cells/well) were seeded in a 96-well plate in 200 μL of RPMI 1640 medium supplemented with previously inactivated 10% fetal bovine serum (FBS), 100 U/mL of penicillin and 100 μg/mL of streptomycin. After that, the cells were treated with different concentrations of bikaverin (0.125, 0.25, 0.5, 0.75 and 1 μg/mL) or vehicle (DMSO, 0.1%, v/v) or positive control (cyclophosphamide at 11 μg/mL) and incubated for 24 h at 37 °C in a humidified atmosphere containing 5% CO_2 [19]. The cytotoxic

effect of bikaverin against lymphoma cells was determined by WST-1 assay, according to the instructions provided by the manufacturer. Briefly, 20 µL of WST-1 solution was added to each well and incubated for 2 h under the same conditions. The optical density was measured at 540 nm in a microplate reader. The percentage of viable cells was determined by the following equation:

$$Cell\ viability\ (\%) = [Abs\ cells\ treated/Abs\ cells\ not\ treated]*100$$

The data generated was used to plot a dose-response curve which determines the inhibitory concentration $(IC)_{50}$.

In silico Toxicity Prediction

Physicochemical and toxicity parameters were determined in an online screening tool for rodent oral toxicity prediction by PROTOX Software (http://tox.charite.de/tox). The prediction method was based on chemical similarity and identification of fragments that were over-represented in toxic compounds. Qualitative and quantitative data interpretation was released according to the instructions provided by PROTOX software [20,21].

Animals

Adult male BALB/*c* mice (6 weeks old, 25 g) were provided by the Centro de Investigación Biomédica de Occidente (CIBO-IMSS) and were maintained under standard laboratory condition at 22±1 ° C, 55-60% of humidity, 12 h light/dark cycle and food (Purina Lab Chow-México)/water *ad libitum*. All experiments were conducted according to the protocols approved by the NOM-062-ZOO-1999 [22].

Antitumoral Effect

Animals were randomized in four groups (n=5), and each one was inoculated intraperitoneally with 2 x 10^4 L5178Y lymphoma cells (in 0.1 mL of isotonic saline solution) on day zero. Group one was considered the negative control (without treatment). After 24 h; the other groups were treated with cyclophosphamide at 75 mg/kg by intraperitoneal (i.p.) route during three days (group two), and with bikaverin at 1.73 mg/kg/day by i.p. (group three) and oral (group four) administration during 15 days. Afterward, the animals were sacrificed and the peritoneum was washed three times with physiologic saline solution, and the ascitic fluid containing the L5178Y lymphoma cells was collected. Then, 10 µL of the diluted cell suspension was placed on the Neubauer chamber, and the cells were counted. The cell viability was determined by trypan blue assay. The antitumoral effect of bikaverin was assessed by observation of changes with regard to the following parameters: tumor weight (weight variation), ascitic fluid volume and cell density.

Statistical Analysis

Data was statistically analyzed by one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test using the GraphPad Prism software (Version 6.0). *p* values < 0.05 were considered to indicate statistical significance.

Results and discussion

Bikaverin was produced by *G. fujikuroi* fungus in a bioreactor and extracted as previously described [18]. The crude ethyl acetate extract from the biomass was fractioned by column chromatography, and the fractions with bikaverin were recrystallized to obtain the pure compound. The compound was identified by direct comparison with the spectroscopic data of an authentic sample and data described in the literature. The ^{1}H-NMR spectrum showed twelve protons attached to carbon atoms: δ 3.02 (3H, s, 1-Me), δ 4.17 (3H, s, 8-OMe), δ 4.19 (3H, s, 3-OMe), δ 6.83 (1H, s, H-9), δ 7.36 (1H, s, H-2) and δ 7.43 (1H, s, H-4). The ^{13}C-NMR spectrum showed signals due to the aromatic methyl group at δ 23.3 (1-Me), methoxy groups at δ 57.5 (3-OMe) and δ 58.0 (8-OMe) as well as three carbons directly bonded to hydrogen at δ 100.1 (CH-4), δ 109.3 (CH-9)

and δ 124.2 (CH-2). The NMR spectral data was identical to those of bikaverin previously reported [11,23,24]. Thus, the compound was identified as bikaverin (Fig. 1.).


Fig. 1. Chemical structure of bikaverin

Bikaverin was evaluated against the L5178Y lymphoma cells at various concentrations (0.125 to 1 μg/mL) to determine its cytotoxic effect. The results showed that the cells were sensitive to the bikaverin treatment in a dose-dependent manner. The compound showed a significant cytotoxic effect with an IC_{50} value of 0.23 μg/mL while cyclophosphamide (positive control) showed an IC_{50} value of 11 μg/mL (Fig. 2.).


Fig. 2. Cytotoxic effect of bikaverin on L5178Y lymphoma cells. The values are represented as mean $\pm$ S.D of three independent experiments (n=3). Significance was determined using ANOVA followed by Dunnett's multiple comparisons test. Bikaverin and cyclophosphamide (CY) were compared with control group (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$).

The LD_{50} for laboratory animals was determined in the ProTox web server. According to the oral toxicity prediction, the value of LD_{50} for bikaverin was 16 mg/kg, which corresponds to class II toxicity compounds (LD_{50} with $5 \leq 50$ mg/kg). This value is important for future experiments such as antitumoral activity evaluation in order to establish the therapeutic dose in mice.

Bikaverin at 1.73 mg/kg/day was evaluated on L5178Y lymphoma murine model to assess the antitumoral effect by either i.p. (group three) or oral (group four) administration. The parameters such as the tumor weight (weight variation), ascitic fluid volume and cell density were analyzed. The results showed that the control group (without treatment) had a weight variation of 4.25±1.03 g while the groups treated with bikaverin reduced the weight variation significantly, and showed 1.5±0.57 g (i.p.) and 1.2±0.36 g (oral), respectively (Fig. **3A**). On other hand, in the groups treated with bikaverin, the ascitic fluid volume and cell density were reduced significantly. In this context, the control group showed 3.43±0.78 mL of ascitic fluid and bikaverin groups showed 1.1±0.79 mL (i.p.) and 0.84±0.6 mL (oral), respectively (Fig. **3B**). Finally, the cell density in mice without treatment (control) was 1,280±128 x 10^5 cells/mL and the groups treated with bikaverin showed 391.5±237 x 10^5 cells/mL (i.p.) and 580±208 x 10^5 cells/mL (oral), respectively (Fig. **3C**). The *in vivo* study results showed that bikaverin had a significant antitumoral effect on L5178Y lymphoma in mice and were consistent with the *in vitro* study results.

Fig. 3. Antitumoral effect of bikaverin on L5178Y lymphoma murine model by weight variation (**3A**), ascitic fluid volume (**3B**) and cell density (**3C**). The values are presented as mean ± S.D (n=5). Significance was determined using ANOVA followed by Dunnett´s multiple comparisons test. Bikaverin and cyclophosphamide (Cy) were compared with control group (*** $p < 0.001$; **** $p < 0.0001$).

Bikaverin has gained the attention of researchers for its advantageous biological effects such as antiprotozoal, antifungal, nematicidal, neuroprotective and cytotoxic effect [8,13]. About the last, bikaverin and its derivatives have been effective against the following tumor cell lines: Ehrlich ascites carcinoma (ED_{50}=0.5 µg/mL), leukemia L5178 (ED_{50}=1.4 µg/mL) and sarcoma (ED_{50}=4.2 µg/mL) [16]. It has been shown that bikaverin inhibits ATP synthesis and, hence, energy metabolism in Ehrlich ascites tumor cells [14]. Also, it was considered an uncoupler of oxidative phosphorylation in tumor cell line P388 [15]. The effect of bikaverin on respiration was reexamined in isolated rat liver mitochondria, and the results showed that the uncoupling effect was only produced at high concentrations as a consequence of disturbing ion permeability of the mitochondrial inner membrane, and at low concentration, bikaverin repressed NAD- and succinate-linked respirations, but did not interfere with electron transport and energy transfer systems of mitochondria [8,25]. Also, the cytotoxic effect of bikaverin has been evaluated against a panel of four human tumor cell lines, non-small cell lung (NCI-H460, IC_{50}=0.43 µM), pancreatic (MIA Pa Ca-2, IC_{50}=0.26 µM), breast (MCF-7, IC_{50}=0.42 µM) and CNS glioma (SF-268, IC_{50}=0.38 µM) [17]. Recently, bikaverin was evaluated in human protein kinase (casein kinase 2; CK2) activity and showed inhibitory effect with an IC_{50} value of 1.24 µM. This enzyme is implicated in many cellular processes and is highly expressed and active in many tumor cells. CK2 enhances cancer phenotype by suppressing apoptosis and stimulating cell growth. For this reason, the inhibition of CK2 is important to induce the physiological process of apoptosis, leading to tumor cell death [26]. In addition, bikaverin was not genotoxic and cytotoxic in primary rat hepatocytes at low concentrations (<100µM) and had not affect the cell viability on differentiated intestinal porcine epithelial cells (IPEC-J2) at 5-10 µM [27,28].

In this research, the cytotoxic effect of bikaverin was tested on L5178Y lymphoblast and showed an IC_{50} value of 0.23 µg/mL. This result supports the cytotoxic effect of bikaverin against tumor cell lines and shows its pharmacological importance because cytotoxic compounds with an IC_{50} lower than 4 µg/mL are considered promising for the research of new anticancer agents [29]. For the *in vivo* model, the LD_{50} (16 mg/kg) was determined *in silico* using the PROTOX software and was reduced approximately 10 times considering the solubility of bikaverin. Thus, a dose of 1.73 mg/kg/day of bikaverin was administered by i.p. and oral administration to the mice BALB/c inoculated with L5178Y lymphoma cells. The results showed that bikaverin inhibited significantly the tumor development (weight variation, ascitic fluid, and cell density). Although the cytotoxic effect of bikaverin has been reported, this is the first time that the antitumoral effect (*in vivo*) of bikaverin is reported and the results show the potential of bikaverin as an antitumoral compound. The

aforementioned is important because other factors are present in the *in vivo* model. For example, the compound could be altered in the *in vivo* model by metabolism and lose its effect. In addition, other key pharmacokinetic parameters such as tissue uptake, bioavailability, absorption and distribution could affect the antitumoral effect of the compound in an organism. Finally, to continue the studies, chemical derivatives of bikaverin could be prepared and their effect tested by structure-activity relationship studies on protein kinase CK2 and cancer cell lines. With regard to the *in vivo* model, pharmacokinetics, pharmacodynamics and toxicology studies are necessary.

Conclusion

Natural products are relevant to drug discovery, and fungi is a valuable source of novel compounds that could be used to develop new drugs to the treatment of diseases. In this research, we determined experimentally that bikaverin isolated from *G. fujikuroi* is cytotoxic on L5178Y lymphoblast at low concentrations in a dose-dependent manner, and it showed potential as an antitumoral compound in mice by either i.p. or oral administration. Our *in vitro* and *in vivo* results suggest that bikaverin could be considered a promising compound to the development of new anticancer agents.

Acknowledgments

References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R. L.; Torre, L. A.; Jemal, A. *CA: Cancer J. Clin.* **2018**, 68, 394-424.
2. Roodhart, J. M. L.; Daenen, L. G. M.; Stigter, E. C. A; Prins, H. J.; Gerrits, J.; Houthuijzen, J. M.; Gerritsen, M. G.; Schipper, H. S.; Backer, M. J. G.; van Amersfoort, M.; Vermaat, J. S. P.; Moerer, P.; Ishihara, K.; Kalkhoven, E.; Beijnen, J. H.; Derksen, P. W. B.; Medema, R. H.; Martens, A. C.; Brenkman, A. B.; Voest, E. E. *Cancer Cell* **2011**, 20, 370–383.
3. Atmaca, H.; Çamli, C.; Sert, S. *Celal Bayar University Journal of Science* **2018**, 14, 35-40.
4. Newman, D. J.; Cragg, G. M. *J. Nat. Prod.* **2016**, 79, 629–661.
5. Espinoza, C.; Couttolenc, A.; Fernández, J. J.; Norte, M.; Plata, G. B.; Padrón, J. M.; Shnyreva, A.; Trigos, A. *J. Mex. Chem. Soc.* **2016**, 60, 79-82.
6. Bugni, T. S.; Ireland, C. M. *Nat. Prod. Rep.* **2004**, 21, 143-163.
7. Kharwar, R. N.; Mishra, A.; Gond, S. K.; Stierle, A.; Stierle, D. *Nat. Prod. Rep.* **2011**, 28, 1208-1228.
8. Limón, M. C.; Rodríguez-Ortiz, R.; Avalos, J. *Appl. Microbiol. Biotechnol.* **2010**, 87, 21-29.
9. Schumacher, J.; Gautier, A.; Morgant, G.; Studt, L.; Ducrot, P.-H.; Le Pêcheur, P.; Azeddine, S.; Fillinger, S.; Leroux, P.; Tudzynski, B.; Viaud, M. *PloS One*. **2013**, 8, e53729-e53742.
10. Balan, J.; Fuska, J.; Kuhr, I.; Kuhrová, V. *Folia Microbiol.* **1969**, 15, 479–484.
11. Son, S. W.; Kim, H. Y.; Choi, G. J.; Lim, H. K.; Jang, K. S.; Lee, S. O.; Lee, S.; Sung, N. D.; Kim, J.-C. *J. Appl. Microbiol.* **2008**, 104, 692–698.
12. Kwon, H. R.; Son, S. W.; Han, H. R.; Choi, G. J.; Jang, K. S.; Choi, Y. H.; Lee, S.; Sung, N. D.; Kim, J.-C. *Plant Pathol. J.* **2007**, 23, 318–321.
13. Nirmaladevi, D.; Venkataramana, M.; Chandranayaka, S.; Ramesha, A; Jameel, N. M.; Srinivas, C. *Cell. Mol. Neurobiol.* **2014**, 34, 973–985.
14. Henderson, J. F.; Battell, M. L.; Zombor, G.; Fuska, J.; Nemec, P. *Biochem. Pharmacol.* **1977**, 26, 1973–1977.

15. Kovac, L.; Bohmerova, E.; Fuska, J. *J. Antibiot.* **1978**, 31, 616–620.
16. Fuska, J.; Proksa, B.; Fusková, A. *Neoplasma.* **1975**, 22, 335–338.
17. Zhan, J.; Burns, A. M.; Liu, M. X.; Faeth, S. H.; Gunatilaka, A. A. L. *J. Nat. Prod.* **2007**, 70, 227–232.
18. Chavez-Parga, M. C.; Hinojosa-Ventura, G.; Maya-Yescas, R.; Gonzalez-Hernandez, J. C. *Int. Rev. Chem. Eng.* **2014**, 6, 100–107.
19. Navarro-Salcedo, M. H.; Delgado-Saucedo, J. I.; Siordia-Sánchez, V. H.; González-Ortiz, L. J.; Castillo-Herrera, G. A.; Puebla-Pérez, A. M. *J. Med. Food.* **2017**, 20, 1076-1082.
20. http://tox.charite.de/tox/index.php?site=compound_search_similarity
      (accessed on November 16, **2017**).
21. Banerjee, P.; Erehman, J.; Gohlke, B.-O.; Wilhelm, T.; Preissner, R.; Dunkel, M. *Nucleic Acids Res.* **2015**, 43, D935–D939.
22. Secretaría de Agricultura Ganadería, Desarrollo Rural, Pesca y Alimentación: Norma Oficial Mexicana NOM-062-ZOO-1999, Especificaciones técnicas para la producción, cuidado y uso de animales de laboratorio, Edited by Diario Oficial de la Federación. **2001**.
23. Kjaer, D.; Kjaer, A.; Pedersen, C.; Bu´Lock, J. D.; Smith, J. R. *J. Chem. Soc.* **1971**, 1, 2792–2797.
24. Mcinnes, A. G.; Walter, J. A.; Smith, D. G.; Wright, J. L. C.; Vining, L. C. *J. Antibiot.* **1976**, 29, 1050–1057.
25. Suzuki, T.; Kitagawa, A.; Kawai, K.; Hamasaki, T. *Micotoxin Res.* **1998**, 14, 19–27.
26. Haidar, S; Bouaziz, Z.; Marminon, C.; Laitinen, T.; Poso, A.; Le Borgne, M.; Jose, J. *Pharmaceuticals*. **2017**, 10, 1–13.
27. Norred, W. P.; Plattner, R. D.; Vesonder, R. F.; Bacon, C. W.; Voss, K. A. *Food Chem. Toxicol.* **1992**, 30, 233-237.
28. Springler, A.; Vrubel, G.-J.; Mayer, E.; Schatzmayr, G.; Novak, B. *Toxins* **2016**, 8, 345-365.
29. Jacobo-Herrera, N. J.; Jacobo-Herrera, F. E.; Zentella-Dehesa, A.; Andrade-Cetto, A.; Heinrich, M.; Pérez-Plasencia, C. *J. Ethnopharmacol.* **2016**, 179, 391–402.